Publications
Banerjee, S., Dowsett, M., Ashworth, A. and Martin, L.A. Mechanisms of disease: angiogenesis and the management of breast cancer.
Nat Clin Pract Oncol (2007) 4, 536-550.
Johnston SR, Leary A, Martin LA, Smith IE, Dowsett M. Enhancing endocrine response with novel targeted therapies : why have the clinical trials to date failed to deliver on the preclinical promise?
Cancer. 2007 Dec
Martin, L.A., Head, J.E., Pancholi, S., Salter, J., Quinn, E., Detre, S., Kaye, S., Howes, A., Dowsett, M. and Johnston, S.R. The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Mol Cancer Ther (2007) 6, 2458-2467.
Urruticoechea A, Aguilar H, Solé X, Capellà G, Martin LA, Dowsett M, Germà-Lluch JR. Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of postmenopausal hormone-sensitive breast cancer.
Breast Cancer Res Treat. 2007 Jul 19; [Epub ahead of print]
Johnston SR, Martin LA, Leary A, Head J, Dowsett M. Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer.
J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):180-6
Hilmi C, Larribere L, Giuliano S, Bille K, Ortonne JP, Ballotti R, Bertolotto C. IGF1 Promotes Resistance to Apoptosis in Melanoma Cells through an Increased Expression of BCL2, BCL-X(L), and Survivin.
J Invest Dermatol 2007 Dec 13;[Epub ahead of print]
Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease:angiogenesis and the management of breast cancer.
Nat Clin Pract Oncol. 2007 Sep 4; (9):536-50
Banerjee, S., Reis-Filho, J.S., Ashley, S., Steele, D., Ashworth, A., Lakhani, S.R. and Smith, I.E. Basal-like breast carcinomas: clinical outcome and response to chemotherapy.
J Clin Pathol (2006) 59: 729-735
Folkerd, E.J., Martin, L.A., Kendall, A., Dowsett, M. The relationship between factors affecting endogenous oestradiol levels in postmenopausal women and breast cancer.
J Steroid Biochem Mol Biol. (2006) 102, 250-5.
Dowsett, M., Johnston, S., Martin, L.A., Salter, J., Hills, M., Detre, S., Gutierrez, M.C., Mohsin, S.K., Shou, J., Allred, D.C., Schiff, R., Osborne, C.K. and Smith, I. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
Endocr Relat Cancer. (2005a) 12 Suppl 1: S113-117
Dowsett, M., Martin, L.A., Smith, I. and Johnston, S. Mehanisms of resistance to aromatase inhibitors.
J Steroid Biochem Mol Biol. (2005) 95: 167-172
Gee, J.M., Howell, A., Gullick, W.J., Benz, C.C., Sutherland, R.L., Santen, R.J., Martin, L.A., Ciardiello, F., Miller, W.R., Dowsett, M., Barrett-Lee, P., Robertson, J.F., Johnston, S.R., Jones, H.E., Wakeling, A.E., Duncan, R. and Nicholson, R.I. Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.
Endocr Relat Cancer. (2005) Suppl 1: S1-7
Johnston, S.R., Martin, L.A. and Dowsett, M. Life following aromatase inhibitors—where now for endocrine sequencing?
Breast Cancer Res Treat. (2005) 93 Suppl 1: S19-25
Johnston, S.R., Martin, L.A., Head, J., Smith, I. and Dowsett, M. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
J Steroid Biochem Mol Biol. (2005) 95: 173-181
Martin, L.A., Pancholi, S., Chan, C.M., Farmer, I., Kimberley, C., Dowsett, M. and Johnston, S.R. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling.
Endocr Relat Cancer. (2005) 12: 1017-1036
Martin, L.A., Farmer, I., Johnston, S.R., Ali, S. and Dowsett, M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
Endocr Relat Cancer. (2005) 12 Suppl 1: S75-84
